International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 20(1), 13-17
This study evaluates the effect of treatment with Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy, and the final outcome of pregnancy and fetal status. One hundred and fifty patients received intramuscular injection of Proluton-Depot from 6 weeks to 8 weeks to 16 weeks to 18 weeks gestation. The outcome of this treated group was compared with a similar number of 150 patients with similar problems, but the second group received no hormonal treatment. There was no evidence to suggest that Proluton-Depot had any adverse effect on the infant or the final outcome of pregnancy.
Varma, T. R., & Morsman, J. (1982). Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, *20*(1), 13-17. https://doi.org/10.1016/0020-7292(82)90039-x
Varma TR, Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet. 1982;20(1):13-17. doi:10.1016/0020-7292(82)90039-x
Varma, T. R., and J. Morsman. "Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy." *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, vol. 20, no. 1, 1982, pp. 13-17.
17 alpha-Hydroxyprogesterone Caproate, Abnormalities, Drug-Induced/etiology, Abortion, Spontaneous/drug Therapy, Adult, Corpus Luteum Maintenance/drug Effects, Female, Humans, Hydroxyprogesterones/adverse Effects/therapeutic Use, Infant, Newborn, Infertility, Female/drug Therapy, Outcome and Process Assessment, Health Care, Pregnancy, Prenatal Exposure Delayed Effects, Hydroxyprogesterones, 17 alpha-Hydroxyprogesterone Caproate